Thromb Haemost 2016; 115(02): 237-239
DOI: 10.1160/th15-05-0412
T&Images
Schattauer GmbH

Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome

Rocco Vergallo
1   Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
,
Aaron D. Aguirre
2   Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
,
Farhad Abtahian
1   Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
,
Yoshiyasu Minami
1   Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
,
Tsunenari Soeda
1   Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
,
Yiannis S. Chatzizisis
2   Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
,
Kevin Croce
2   Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
,
Ik-Kyung Jang
1   Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
3   Division of Cardiology, Kyung Hee University, Seoul, South Korea
› Author Affiliations
Financial support: This study was funded by the Dr. John Nam Research Fellowship grant, and the generous support of Mr. and Mrs. Michael A. Park. Dr. Vergallo is funded by the “Enrico ed Enrica Sovena” Foundation, Rome, Italy. Dr. Aguirre is funded by the American Heart Association (14FTF20380185).
Further Information

Publication History

Received: 16 May 2015

Accepted after major revision: 29 August 2015

Publication Date:
29 November 2017 (online)

 

 
  • References

  • 1 Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368: 1033-1044.
  • 2 George J, Harats D, Gilburd B. et al. Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 2000; 102: 1822-1827.
  • 3 Soeda T, Uemura S, Park SJ. et al. Incidence and Clinical Significance of Post-Stent OCT Findings: One Year Follow-Up Study From a Multicenter Registry. Circulation. 2015 Epub ahead of print.
  • 4 Espinosa G, Cervera R. Current treatment of anti-phospholipid syndrome: lights and shadows. Nat Rev Reumatol. 2015 Epub ahead of print.
  • 5 Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I. et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on Antiphospholipid Antibodies. Lupus 2011; 20: 206-218.
  • 6 Chighizola CB, Moia M, Meroni PL. New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus 2014; 23: 1279-1282.
  • 7 Signorelli F, Nogueira F, Domingues V. et al. Thrombotic events in patients with antiphospholi-pid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol. 2015 Epub ahead of print.
  • 8 Mauri L, Kereiakes DJ, Yeh RW. et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-2166.